Dyne Therapeutics price target raised to $46 from $38 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Dyne Therapeutics (DYN) to $46 from $38 and keeps a Buy rating on the shares. The firm believes Dyne’s dual Breakthrough programs in myotonic dystrophy and Duchenne muscular dystrophy are now entering registrational stages with “validated functional and biomarker data. This positions the company for clinical catalysts and as a strategic takeover asset, the analyst tells investors in a research note. The Avidity acquisition “sets a clear benchmark, and Dyne’s more mature dataset strengthens the case for a higher premium takeout,” contends H.C. Wainwright.